Biotechnology

By Maggie Fox, health and science editor Maggie Fox, health and science Editor-Mountain Nov 22, 6: 19 h. HITTITES WASHINGTON (Reuters)-Christopher Goodrich, Portland, Oregon, can't wait for a needle in his eyes. Goodrich was expected to be one of the first patients were enrolled in clinical trial this only a sound States food and drug administration, only the second judgment approved anywhere in the world test globil human milk stem in the people. Advanced cell technology, a Massachusetts-based company biotechnologie did evil to bring globil human milk stem in the lab to the clinic, recrutement 12 patients start in Oregon, Massachusetts and eye condition called scarce Stargardt (k will be put to death. Goodrich, 55, retired last year of his work as Coordinator for services to the University of Portland State when Stargardt (k death completely inexplicable and suddenly take a turn for the worse. Like most patients Goodrich, saw the vision, it gets worse steadily from his earliest da...

Maggie Fox, health and Science Editor Maggie Fox, health and Science Editor – Mon Nov 22 6 : 19 pm ET, WASHINGTON (Reuters)-Portland, Oregon, Christopher Goodrich can be expected to stick a needle in her eye. Goodrich hopes one clinical research, which received only in the food and drug administration, only the second research accepted throughout the world to test the human embryonic stem cells in humans, the go-ahead of the first patients enrolled in. Advanced cell technology, a small Massachusetts-based biotechnology company, which has struggled to raise the human embryonic stem cell Lab clinic begins recruitment and Massachusetts patients 12 Oregon rare eye condition, i.e. Stargardt's macular dystrophy. Goodrich, 55, retired last year in his job as a coordinator of Portland State University services veteran's macular dystrophy when his Stargardt viewing experience, and suddenly deteriorated. Like most patients Goodrich had seen his Vision to get steadily worse his young adul...